Full access to Entrepreneur for $5
Subscribe

Company News for Sep 10, 2021

Companies In The News Are: LULU, RH, HQY, MRNA

By
This story originally appeared on Zacks
  • Shares of Lululemon Athletica Inc. LULU rallied 10.5% after the company reported fiscal second-quarter 2022 adjusted earnings per share of $1.65, beating the Zacks Consensus Estimate of $1.21.
  • RH’s RH shares rose 7.8% after the company delivered fiscal second-quarter 2022 adjusted earnings per share of $8.48, surpassing the Zacks Consensus Estimate of $6.58.
  • HealthEquity, Inc.’s HQY shares gained 4.4% after the company reported fiscal second-quarter 2022 adjusted earnings per share of $0.40, outpacing the Zacks Consensus Estimate of $0.36.
  • Moderna, Inc.’s MRNA shares advanced 7.8% after the company announced that it is developing a single-shot vaccine that combines booster shots against COVID-19 as well as the seasonal flu, and the new vaccine is called mRNA-1073.


Bitcoin, Like the Internet Itself, Could Change Everything

- Zacks

Blockchain and cryptocurrency has sparked one of the most exciting discussion topics of a generation. Some call it the “Internet of Money” and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we’re still in the early stages of this technology, and as it grows, it will create several investing opportunities.

Zacks’ has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly. 

See 3 crypto-related stocks now >>



Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 

Moderna, Inc. (MRNA): Free Stock Analysis Report

 

lululemon athletica inc. (LULU): Free Stock Analysis Report

 

RH (RH): Free Stock Analysis Report

 

HealthEquity, Inc. (HQY): Free Stock Analysis Report

 

To read this article on Zacks.com click here.

 

Zacks Investment Research